Ipamorelin - what the science actually shows

What Ipamorelin is - and where it comes from

Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed by Novo Nordisk in the late 1990s. It belongs to the growth hormone releasing peptide (GHRP) class - compounds that stimulate the pituitary gland to release growth hormone by acting on the ghrelin receptor (GHSR-1a).

What distinguished Ipamorelin from earlier GHRPs was its selectivity profile. GHRP-6, the first widely studied GHRP, significantly elevates cortisol, prolactin, and ACTH alongside GH. Ipamorelin was developed specifically to minimize these off-target effects, resulting in a compound that produces clean, pulsatile GH release with a narrower hormonal footprint in preclinical models.

Mechanism, in plain English

The pituitary gland releases growth hormone in pulses throughout the day. Ipamorelin binds the GHSR-1a receptor (the ghrelin receptor) on pituitary somatotroph cells and amplifies these pulses. It does not replace the body's existing GH rhythm - it turns up the amplitude of natural pulses rather than creating a sustained flat elevation.

This mechanism-of-action contrasts with exogenous rhGH (recombinant human growth hormone), which creates a continuous non-pulsatile elevation. The physiological significance of pulsatility for downstream IGF-1 signaling is an active area of research.

What the evidence shows

Ipamorelin's evidence base is stronger than most peptides in its class because it was taken into human clinical development. In preclinical studies, Ipamorelin produced dose-dependent GH elevation in rats and pigs with minimal cortisol response. The foundational paper by Raun et al. (1998) in European Journal of Endocrinology established its selectivity profile and differentiated it from GHRP-6.

Novo Nordisk advanced Ipamorelin into Phase II trials. A published study by Svensson et al. (1999) in Journal of Clinical Endocrinology & Metabolism confirmed GH and IGF-1 elevation in healthy volunteers with a clean cortisol profile. A separate trial evaluated Ipamorelin for postoperative ileus (NCT00226434) - GI motility data showed early promise but the program did not continue to Phase III.

No large published RCT exists for recovery, body composition, or any currently common community indication. The clinical data is real but narrow in scope.

FDA status

Ipamorelin is not FDA-approved for any human indication. It was studied by Novo Nordisk but the development program did not result in an approved drug application. It is not currently available as a prescription compound in the US and was subject to the July 2026 FDA advisory panel review on peptide compounding access. Last reviewed 2026-08-09.

Common synonyms researchers use

Ipamorelin  ·  NNC 26-0161  ·  Aib-His-D-2-Nal-D-Phe-Lys-NH2  ·  GHRP-1 variant (informal; technically distinct)

Safety & adverse-event landscape

In Phase II clinical trials, Ipamorelin was generally well tolerated with headache and nausea reported as the most common adverse events. The clean cortisol profile makes it theoretically safer than GHRP-6 for prolonged study periods, though no long-term safety data in humans has been published.

The GH-elevating mechanism raises the same theoretical concerns shared across all GH secretagogues: potential acceleration of undetected neoplasms, fluid retention, and effects on insulin sensitivity. These are hypothetical considerations based on mechanism, not reported outcomes at studied doses. Peptexa does not provide dosing guidance. Consult a qualified provider.

Frequently asked questions